Drug Profile
PMD 026
Alternative Names: PMD-026Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Phoenix Molecular Designs
- Class Antineoplastics; Small molecules
- Mechanism of Action Ribosomal protein S6 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer; Cancer
Highest Development Phases
- Phase I Breast cancer; HER2 negative breast cancer; Prostate cancer; Triple negative breast cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Breast-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Triple-negative-breast-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 06 Dec 2022 Phase I development in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) is ongoing in USA (PO)